BiotechTube
Home/Silence Therapeutics/Dr. Michael G. Attenborough
DM

Dr. Michael G. Attenborough

Chief Business Officer

Silence Therapeutics

Therapeutic Areas

CardiovascularMetabolicHematologic

Silence Therapeutics Pipeline

DrugIndicationPhase
Zerlasiran (SLN360)Elevated Lipoprotein(a) for Cardiovascular Risk ReductionPhase 2
SLN124Iron-Refractory Iron Deficiency Anemia (IRIDA)Phase 2

Leadership Team at Silence Therapeutics

CT
Craig Tooman
President and Chief Executive Officer
DD
Dr. David Horn Solomon
Chief Financial Officer
DK
Dr. Kishor M. Wasan
Chief Medical Officer
DR
Dr. Ralf Rosskamp
Chief Scientific Officer
DI
Dr. Iain Ross
Chairman of the Board
View full Silence Therapeutics profile